• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Chinese Tycoon Eyes $500M IPO of Luye Life Sciences' Clinic Arm

biospaceJanuary 25, 2018

Tag: Luye Life Sciences , IPO

Luye Life Sciences Group, run by acquisitive Chinese entrepreneur Liu Dianbo, is considering a Singapore initial public offering of its health-care services arm that could raise as much as $500 million, people with knowledge of the matter said.

The company’s Luye Medical Group unit plans to evaluate proposals from investment banks as soon as next month, according to the people. The Singapore-based company aims to sell shares later this year, the people said, asking not to be identified as the discussions are private. 

Previous:NIH Gets Into CRISPR/Cas9, Launches $190M Genome Editing Research Program

Next:J&J to Spend More on R&D With Tax Reform Money

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Chinese Tycoon Eyes $500M IPO of Luye Life Sciences' Clinic Arm | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

99% up Sodium Tripolyphosphate CAS NO.7758-29-4

99% up Sodium Tripolyphosphate CAS NO.7758-29-4
Tripotassium Phosphate

Tripotassium Phosphate
Siponimod hemi-fumarate

Siponimod hemi-fumarate
Thioctic Acid(Alpha Lipoic Acid)

Thioctic Acid(Alpha Lipoic Acid)
Alpha Lipoic Acid

Alpha Lipoic Acid
lipoic acid

lipoic acid
cationic liposome DLin-MC3-DMA丨1224606-06-7

cationic liposome DLin-MC3-DMA丨1224606-06-7
dipotassium trioxotellurate

dipotassium trioxotellurate
TLEx SERIES LIPOSOME EXTRUSION EQUIPMENT

TLEx SERIES LIPOSOME EXTRUSION EQUIPMENT
24-carbonyl-1,3-bi-TBS-trans- Calcipotriol

24-carbonyl-1,3-bi-TBS-trans- Calcipotriol

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service